Physician profile
Jeffrey D Hook
NPI 1265409189
$3,577.16
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $334 · 2021: $745 · 2022: $588 · 2023: $850 · 2024: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.11 | 2021-2024 | |
| Pfizer INC. | $440.32 | 2019-2024 | |
| Abbott Laboratories | $252.52 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Novo Nordisk INC | $210.35 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Axsome Therapeutics, INC. | $202.42 | 2022-2023 | Sunosi |
| Lilly USA, LLC | $198.66 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.15 | 2019-2024 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $152.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $116.56 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $87.96 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $83.16 | 2023-2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $74.44 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $72.25 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $67.16 | 2020-2023 | Dificid |
| Novartis Pharmaceuticals Corporation | $66.87 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $64.27 | 2021 | |
| Nestle Healthcare Nutrition INC. | $63.60 | 2021-2023 | |
| Allergan, INC. | $62.90 | 2020-2021 | |
| Amgen INC. | $57.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.81 | 2019-2021 | |
| Eisai INC. | $48.76 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $46.19 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.73 | 2023 | |
| Esperion Therapeutics, INC. | $32.28 | 2024 | Nexletol |
| Therapeuticsmd, INC. | $27.87 | 2019 | |
| Lundbeck LLC | $26.71 | 2023 | Vyepti |
| Astellas Pharma US INC | $25.17 | 2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $24.66 | 2024 | Rexulti |
| Harmony Biosciences LLC | $21.45 | 2024 | |
| Edwards Lifesciences Corporation | $20.94 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.64 | 2019 | |
| Ironwood Pharmaceuticals, INC | $18.04 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.65 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.77 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $13.33 | 2019 | |
| Acerus Pharmaceuticals Corporation | $11.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.